Patent ID: 7662834

Claim:
A method of treating an angiogenesis-mediated disease comprising administering to a subject in need thereof an effective amount of a compound of formula 1: wherein, R 1 is isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 R 5 groups; R 2 is H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 R 5 groups; R 3 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, furyl, thiophenyl, isoxazolyl, thiazolyl, imidazolyl, pyridyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, thionaphthenyl, benzofuranyl, benzimidazolyl, pyrimidinyl, quinolinyl, isoquinolyl, indolyl, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, or tetrahydrofuranyl, each being optionally substituted with 1-4 R 5 groups; each R 4 is independently H, NO 2 , halo, CN, R 7 , OR 7 , CO 2 R 7 , SR 7 , NR 7 R 7 , C(O)R 7 , C(O)NR 7 R 7 , OC(O)R 7 , S(O) 2 R 7 , S(O) 2 NR 7 R 7 , NR 7 C(O)NR 7 R 7 , NR 7 C(O)R 7 , NR 7 (COOR 7 ), NR 7 S(O) 2 NR 7 R 7 , or NR 7 S(O) 2 R 7 , S(O) 2 O R 7 ; n is 0, 1, 2, 3, or 4; each R 5 is independently H, C1-C10 alkyl optionally substituted with 1-4 R 6 groups, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, aryl optionally substituted with 1-4 R 6 groups, furyl, thiophenyl, isoxazlyl, thiazolyl, imidazolyl, pyridyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, thionaphthenyl, benzofuranyl, benzimidazolyl, pyrimidinyl, quinolinyl, isoquinolyl, or indolyl, each optionally substituted with 1-4 R 6 groups, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, or tetrahydrofuranyl, each optionally substituted with 1-4 R 6 groups, halo, haloalkyl, SR 7 , OR 7 , NR 7 R 7 , COOR 7 , NO 2 , CN, C(O)R 7 , C(O)NR 7 R 7 , OC(O)R 7 , S(O) 2 R 7 , S(O) 2 O R 7 , S(O) 2 NR 7 R 7 , NR 7 C(O)NR 7 R 7 , NR 7 C(O)R 7 , NR 7 (COOR 7 ), NR 7 S(O) 2 NR 7 R 7 , or NR 7 S(O) 2 R 7 ; each R 6 is independently C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, halo, haloalkyl, CN, NO 2 , OR 7 , or SO 2 R 7 ; each R 7 is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, aryl, furyl, thiophenyl, isoxazolyl, thiazolyl, imidazolyl, pyridyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, thionaphthenyl, benzofuranyl, benzimidazolyl, pyrimidinyl, quinolinyl, isoquinolyl, indolyl, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, or tetrahydrofuranyl, each optionally substituted with 1-4 R 8 groups; each R 8 is independently H, OH, OR 9 , C1-C10 alkyl, halo, aryl, NO 2 , or CN; and each R 9 is independently H, C1-C10 alkyl, or aryl; each being optionally substituted with 1-4 independent OH, halo, CN, NO 2 , or CO 2 H; the angiogenesis-mediated disease being proliferative retinopathy, psoriasis, or rheumatoid arthritis.